In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs

Journal of Controlled Release

Volumn 102, Issue 2, 2005, Pages 509-520

  Valiveti, Satyanarayana ^a   Hammell, Dana C ^a   Paudel, Kalpana S ^a   Hamad, Mohamed O ^a   Crooks, Peter A ^a   Stinchcomb, Audra L ^a  

^a University of Kentucky   (United States)

Author keywords

Guinea pig; Naltrexone; Pharmacokinetics; Prodrugs; Transdermal drug delivery

Indexed keywords

NALTREXONE (NTX); NTX-3-0-ACETATE (ACE-NTX); NTX-3-0-HEXANOATE (HEX-NTX); NTX-3-0-PROPIONATE (PROP-NTX); TRANSDERMAL THERAPEUTIC SYSTEMS (TTS);

ALCOHOLS; CONCENTRATION (PROCESS); ESTERS; PHARMACOKINETICS; PHYSICAL PROPERTIES; PLASMA APPLICATIONS;

DRUG PRODUCTS;

NALTREXONE 3 O ACETATE; NALTREXONE 3 O HEXANOATE; NALTREXONE 3 O PROPIONATE; NALTREXONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; FEMALE; GUINEA PIG; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SKIN PENETRATION; SKIN PERMEABILITY; STEADY STATE; TRANSDERMAL PATCH;

ACETATES; ADMINISTRATION, CUTANEOUS; ANIMALS; AREA UNDER CURVE; CAPROATES; DRUG DELIVERY SYSTEMS; ESTERS; FEMALE; GUINEA PIGS; INJECTIONS, INTRAVENOUS; MALE; MEMBRANES, ARTIFICIAL; NALTREXONE; NARCOTIC ANTAGONISTS; PERMEABILITY; PRODRUGS; PROPIONATES; SKIN ABSORPTION;

EID: 11844249904     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.10.005     Document Type: Article

References (25)

1. A.E. Takemori, and P.S. Portoghese Selective naltrexone-derived opioid receptor antagonists Annu. Rev. Pharmacol. Toxicol. 32 1992 239 269
2. J.R. Volpicelli, A.I. Alterman, and M. Hayashida Naltrexone in the treatment of alcohol dependence Arch. Gen. Psychiatry 49 1992 876 880
3. L. Terenius Rational treatment of addiction Curr. Opin. Chem. Biol. 2 1998 541 547
4. PDR Generics Medical Economics 2nd ed. 1996 2229 2233 New Jersey
5. J.R. Volapicelli, K.C. Rhines, J.S. Rhines, L.A. Volpicelli, A.I. Alterman, and C.P. O'Brien Naltrexone and alcohol dependence. Role of subject compliance Arch. Gen. Psychiatry 54 1997 737 742
6. K. Verebey The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics NIDA Res. Monogr. 28 1980 147 158
7. R.S. Croop, E.B. Faukner, and D.F. Labriola The safety profile of naltrexone in the treatment of alcoholism. Results from the multicentre usage study. The naltrexone usage group study Arch. Gen. Psychiatry 54 1997 1130 1135
8. A.C. King, J.R. Volpicelli, M. Gunduz, C.P. O'Brien, and M.J. Kreek Naltrexone biotransformation and incidence of subjective side effects: a preliminary study Alcohol., Clin. Exp. Res. 21 1997 906 909
9. C.N. Chiang, L.E. Hollister, A. Kishimoto, and G. Barnett Kinetics of naltrexone sustained-release preparation Clin. Pharmacol. Ther. 36 1984 704 708
10. H.R. Kranzler, V. Modesto-Lowe, and E.S. Nuwayser Sustained-release naltrexone for alcoholism treatment: a preliminary study Alcohol., Clin. Exp. Res. 22 1998 1074 1079
11. R.H. Reuning, S.H. Liao, and S.E. Staubus Pharmacokinetic quantitation of naltrexone release from several sustained-release delivery systems NIDA Res. Monogr. 38 1981 172 184
12. A. Naik, Y.N. Kalia, and R.H. Guy Transdermal drug delivery: overcoming the skin's barrier function Pharm. Sci. Technol. Today 3 2000 318 326
13. A.L. Stinchcomb, P.W. Swaan, O. Ekabo, K.E. Harris, J. Browe, D.C. Hammell, T.A. Cooperman, and M. Pearsall Straight-chain naltrexone ester prodrugs: diffusion and concurrent biotransformation in human skin J. Pharm. Sci. 91 2002 2571 2578
14. M.A. Hussain, C.A. Koval, M.J. Myers, E.G. Shami, and E. Shefter Improvement of the oral bioavailability of naltrexone in dogs: a prodrug approach J. Pharm. Sci. 76 1987 356 358
15. K. Verebey, J. Volavka, S.J. Mule, and R.B. Resnick Naltrexone: disposition, metabolism, and effects after acute and chronic dosing Clin. Pharmacol. Ther. 20 1976 315 328
16. M.J. Kogan, K. Verebey, and S.J. Mule Estimation of systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration Res. Commun. Chem. Pathol. Pharmacol. 18 1977 29 34
17. R.H. Reuning, V.K. Batra, T.M Ludden, M.Y. Jao, B.E Sams, M.S. Bathala, A.E. Staubus, and L. Malspeis Plasma naltrexone kinetics after intravenous bolus administration in dogs and monkeys J. Pharm. Sci. 68 1979 411 416
18. N.L. Pac, R.G. Parrish, M.M. Lieberman, K.C. Wong, and R.A. Blatnick Pharmacokinetics of naltrexone and naltrexol in the dog J. Pharmacol. Exp. Ther. 208 1979 254 256
19. E.R. Garrett, and A.E.A. El-Koussi Pharmacokinetics of morphine and its surrogates: V. Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose J. Pharm. Sci. 74 1985 50 56
20. R.H. Reuning, S.B. Ashcraft, J.N. Willey, and B.E. Morrison Disposition and pharmacokinetics of naltrexone after intravenous and oral administration in rhesus monkeys Drug Metab. Dispos. 17 1989 583 589
21. R.L. Bronaugh, and R.F. Stewart Methods for in vitro percutaneous absorption studies. III: hydrophobic compounds J. Pharm. Sci. 73 1984 1255 1258
22. M.E. Wall, D.R. Brine, and M. Perez-Reyes Metabolism and disposition of naltrexone in man after oral and intravenous administration Drug Metab. Dispos. 9 1981 369 375
23. W.J. Roberts, and K.B. Sloan Correlation of aqueous and lipid solubilities with flux for prodrugs of 5-fluorouracil, theophylline, and 6-mercaptopurine: a Potts-Guy approach J. Pharm. Sci. 88 1999 515 522
24. S. Valiveti, D.C. Hammell, D.C. Earles, and A.L. Stinchcomb Transdermal delivery of the synthetic cannabinoid WIN 55,212-2: in vitro in vivo correlation Pharm. Res. 21 2004 1137 1145
25. R.H. Guy, and J. Hadgraft Rate control in transdermal drug delivery? Int. J. Pharm. 82 1992 R1 R6